Lantheus Holdings, Inc. $LNTH Shares Acquired by Sector Gamma AS

Sector Gamma AS increased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 28.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,403 shares of the medical equipment provider’s stock after purchasing an additional 14,102 shares during the quarter. Sector Gamma AS owned approximately 0.09% of Lantheus worth $3,303,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. Elevation Point Wealth Partners LLC acquired a new position in Lantheus in the second quarter valued at $26,000. First Horizon Corp purchased a new stake in shares of Lantheus during the 3rd quarter worth about $26,000. Osterweis Capital Management Inc. acquired a new stake in Lantheus during the 2nd quarter worth approximately $36,000. Tripletail Wealth Management LLC purchased a new position in Lantheus in the third quarter valued at approximately $68,000. Finally, EverSource Wealth Advisors LLC lifted its position in Lantheus by 190.2% during the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after buying an additional 698 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $67.51 on Friday. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $111.29. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. The business’s fifty day moving average price is $63.52 and its two-hundred day moving average price is $60.42. The firm has a market capitalization of $4.48 billion, a PE ratio of 28.37 and a beta of -0.11.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 EPS for the quarter, hitting the consensus estimate of $1.27. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The business had revenue of $384.01 million during the quarter, compared to analyst estimates of $363.42 million. During the same quarter in the prior year, the firm earned $1.70 earnings per share. The company’s quarterly revenue was up 1.4% on a year-over-year basis. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. On average, research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Wall Street Analyst Weigh In

LNTH has been the topic of a number of recent analyst reports. The Goldman Sachs Group set a $77.00 target price on Lantheus and gave the company a “neutral” rating in a research report on Wednesday, October 8th. Mizuho raised their price objective on shares of Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Truist Financial boosted their target price on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Finally, Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Lantheus has a consensus rating of “Moderate Buy” and an average price target of $78.00.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.